ScienceGuardians

ScienceGuardians

Did You Know?

ScienceGuardians gives voice to all stakeholders

Potential therapeutics and vaccines: Current progress and challenges in developing antiviral treatments or vaccines for Oropouche virus

Authors: Abhishek Vijukumar,Aryan Kumar,Hardik Kumar
Journal: Diagnostic Microbiology and Infectious Disease
Publisher: Elsevier BV
Publish date: 2025-3
ISSN: 0732-8893 DOI: 10.1016/j.diagmicrobio.2025.116699
View on Publisher's Website
Up
0
Down
::

Where exactly does the 99.9% inhibition value come from? Is there a primary in vitro study testing acridones specifically against OROV that reports this number? If so, why is it not cited directly instead of a 2024 review?

Did you verify whether Saivish et al. (2024) actually presents original experimental data for this claim, or does it itself cite an earlier study?
If the latter, why was the primary source omitted?

Given that acridones’ mechanism is discussed alongside binding to HSV-1 endonuclease, is it possible this efficacy figure was originally from a different virus and inappropriately generalized to OROV? 

  • You must be logged in to reply to this topic.